Janssen sues Mylan to block generic of schizophrenia drug

29-09-2020

Muireann Bolger

Janssen sues Mylan to block generic of schizophrenia drug

Michael Vi / Shutterstock.com

A Johnson & Johnson (J&J) company, Janssen Pharmaceuticals, is seeking a court order blocking Mylan from making copies of its schizophrenia treatment, Invega Trinza, until its patent expires in 2036.


Janssen, Mylan, generics, schizophrenia, patent infringement, J&J, FDA, Invega Trinza, treatment, commercial manufacture, cancer medication

LSIPR